Sign In
Buy KOD
$33.87
+0.655 (+1.97%)
At Close: Jun 03, 2026
Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
06:00am, Tuesday, 07'th Jan 2025
PALO ALTO, Calif. , Jan. 7, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates
10:21am, Monday, 06'th Jan 2025
Kodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases.
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
11:32am, Thursday, 26'th Dec 2024
Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025.
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential
11:45am, Tuesday, 10'th Dec 2024
Kodiak stock surges as Jefferies upgrades it to a "BUY" rating based on the significant potential of its pipeline candidates for retinal disease indications.
Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock
12:33pm, Monday, 09'th Dec 2024
Jefferies has upgraded Kodiak Sciences Inc. KOD, a biopharmaceutical company focused on retinal (eye) diseases.
Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy?
10:56am, Monday, 25'th Nov 2024
Kodiak Sciences Inc. (KOD) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, KOD's 50-day simple moving average crossed above i
Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus
10:51am, Friday, 15'th Nov 2024
KOD reports a narrower-than-expected loss for the third quarter of 2024. The company provides updates regarding its pipeline development plans.
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results
04:01pm, Thursday, 14'th Nov 2024
PALO ALTO, Calif. , Nov. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2024.
Kodiak Sciences to Participate in Upcoming Investor Conferences
06:15am, Monday, 11'th Nov 2024
PALO ALTO, Calif. , Nov. 11, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics t
Kodiak Sciences to Present at Innovate Retina 2024
05:35pm, Monday, 14'th Oct 2024
PALO ALTO, Calif. , Oct. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics t
Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks
11:06am, Thursday, 10'th Oct 2024
KOD is evaluating tarcocimab in a phase III diabetic retinopathy study, which is set to form the basis for a regulatory filing across three eye disease indications.
Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time
06:00am, Monday, 23'rd Sep 2024
NEW YORK , Sept. 23, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), will host its Investor R&D Day today in New York.
Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City
04:05pm, Tuesday, 17'th Sep 2024
PALO ALTO, Calif. , Sept. 17, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics
Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report?
12:31pm, Friday, 13'th Sep 2024
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus
11:45am, Friday, 16'th Aug 2024
Kodiak (KOD) reports a narrower-than-expected loss for the second quarter of 2024. The company provides updates regarding its pipeline development plans.
